Report

Version of Safety Report ID3Safety Report ID11873500primarysourcecountryUSoccurcountryUStransmissiondateformat102transmissiondate13/01/2021reporttype1serious1seriousnessother1receivedateformat102Date Received28/12/2015receiptdateformat102Date Last Updated15/12/2020fulfillexpeditecriteria1companynumbUS-JAZZ-2015-US-022346duplicate1

Report Duplicate

duplicatesourceJAZZduplicatenumbUS-JAZZ-2015-US-022346

Primary Source

reportercountryUSqualification3

Sender

sendertype2senderorganizationFDA-Public Use

Receiver

receivertype6receiverorganizationFDA

Patient

SexMale

Reaction

1)

reactionmeddraversionpt23.1ReactionCataplexyOutcomeNot recovered/not resolved

2)

reactionmeddraversionpt23.1ReactionDizzinessOutcomeUnknown

3)

reactionmeddraversionpt23.1ReactionHeart rate increasedOutcomeRecovering/resolving

4)

reactionmeddraversionpt23.1ReactionTremorOutcomeUnknown

5)

reactionmeddraversionpt23.1ReactionFlushingOutcomeNot recovered/not resolved

Drug

1)

drugcharacterization1medicinalproductXYREMdrugauthorizationnumb021196drugdosagetextDOSE ADJUSTMENTSdrugdosageformORAL SOLUTIONdrugadministrationroute048drugindicationCATAPLEXYdrugstartdateformat602drugstartdate//2015drugenddateformat602drugenddate//2015actiondrug1drugadditional1

activesubstance

activesubstancenameSODIUM OXYBATE

openFDA Info on Medication

Application NumberNDA021196Brand NameXYREMGeneric NameSODIUM OXYBATEManufacturersJazz Pharmaceuticals, Inc.product_ndc68727-100Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSODIUM OXYBATERXCUI349482, 352257spl_id507868f6-2c1d-488d-8132-38d23218caf3spl_set_id926eb076-a4a8-45e4-91ef-411f0aa4f3caPackage NDC68727-100-01UNII7G33012534

2)

drugcharacterization2medicinalproductADDERALLdrugstructuredosagenumb30drugstructuredosageunit003drugdosagetext30 MG, UNKdrugdosageformCAPSULEdrugstartdateformat102drugstartdate10/11/2015drugrecurreadministration3

activesubstance

activesubstancename AMPHETAMINE ASPARTATE\AMPHETAMINE SULFATE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMP ...

openFDA Info on Medication

Application NumberANDA040422, NDA021303Brand NameADDERALL, ADDERALL XRGeneric Name DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, ... ManufacturersTeva Pharmaceuticals USA, Inc., Takeda Pharmaceuticals America, Inc.product_ndc 57844-105, 57844-117, 57844-110, 57844-112, 57844-115, 57844-120, 57844-130, 540 ... Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive Ingredients AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHA ... RXCUI 541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, ... spl_id12989a25-f31c-4550-9b5d-f354f7f0af45, e3546445-6a4a-46a2-af40-026167005259spl_set_idf22635fe-821d-4cde-aa12-419f8b53db81, aff45863-ffe1-4d4f-8acf-c7081512a6c0Package NDC 57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120- ... UNIIJJ768O327N, O1ZPV620O4, G83415V073, 6DPV8NK46S

3)

drugcharacterization2medicinalproductSYNTHROIDdrugdosagetextUNKdrugdosageformTABLETdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat102drugstartdate11/02/2015drugrecurreadministration3

activesubstance

activesubstancenameLEVOTHYROXINE SODIUM

openFDA Info on Medication

Application NumberNDA021402Brand NameSYNTHROIDGeneric NameLEVOTHYROXINE SODIUMManufacturersAbbVie Inc.product_ndc 0074-3727, 0074-7149, 0074-4341, 0074-4552, 0074-5182, 0074-6624, 0074-6594, 007 ... Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsLEVOTHYROXINE SODIUMRXCUI 892246, 892251, 892255, 966158, 966171, 966185, 966191, 966201, 966205, 966218, ... spl_ided6f6960-2439-4bb0-bb7f-c7d05e4d37a5spl_set_id1e11ad30-1041-4520-10b0-8f9d30d30fccPackage NDC 0074-7149-90, 0074-7149-19, 0074-4341-13, 0074-4341-90, 0074-4341-19, 0074-4341- ... UNII9J765S329G

4)

drugcharacterization2medicinalproductTURMERIC [CURCUMA LONGA]drugdosagetextUNKdrugindicationINFLAMMATIONdrugrecurreadministration3

activesubstance

activesubstancenameHERBALS\TURMERIC

5)

drugcharacterization1medicinalproductXYREMdrugauthorizationnumb021196drugstructuredosagenumb2.25drugstructuredosageunit002drugdosagetext2.25 G, BIDdrugdosageformORAL SOLUTIONdrugadministrationroute048drugindicationNARCOLEPSYdrugstartdateformat610drugstartdate/03/2015drugenddateformat602drugenddate//2015actiondrug1drugadditional1

activesubstance

activesubstancenameSODIUM OXYBATE

openFDA Info on Medication

6)

drugcharacterization2medicinalproductLUNESTAdrugdosagetextUNKdrugdosageformTABLETdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat102drugstartdate01/01/2008drugenddateformat102drugenddate06/03/2015drugrecurreadministration3

activesubstance

activesubstancenameESZOPICLONE

openFDA Info on Medication

Application NumberNDA021476Brand NameLUNESTAGeneric NameESZOPICLONEManufacturersSunovion Pharmaceuticals Inc.product_ndc63402-190, 63402-191, 63402-193Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsESZOPICLONERXCUI485440, 485442, 485465, 540407, 540409, 540411spl_id4c2704d7-3027-4240-9073-3f0b24cf15b5spl_set_idfd047b2b-05a6-4d99-95cb-955f14bf329fPackage NDC 63402-190-30, 63402-191-03, 63402-191-10, 63402-191-01, 63402-191-30, 63402-193- ... UNIIUZX80K71OE

7)

drugcharacterization1medicinalproductXYREMdrugauthorizationnumb021196drugstructuredosagenumb4.25drugstructuredosageunit002drugdosagetext4.25 G, BIDdrugdosageformORAL SOLUTIONdrugadministrationroute048drugstartdateformat602drugstartdate//2015actiondrug1drugadditional1

activesubstance

activesubstancenameSODIUM OXYBATE

openFDA Info on Medication

8)

drugcharacterization1medicinalproductXYREMdrugauthorizationnumb021196drugstructuredosagenumb3.75drugstructuredosageunit002drugdosagetext3.75 GRAM, BIDdrugdosageformORAL SOLUTIONdrugadministrationroute048actiondrug1drugadditional1

activesubstance

activesubstancenameSODIUM OXYBATE

openFDA Info on Medication

9)

drugcharacterization2medicinalproductCREATINEdrugdosagetextUNKdrugdosageformPOWDERdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat102drugstartdate26/03/2015drugrecurreadministration3

activesubstance

activesubstancenameCREATINE

10)

drugcharacterization2medicinalproductLOVAZAdrugdosagetextUNKdrugdosageformCAPSULEdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat102drugstartdate01/01/2008drugrecurreadministration3

activesubstance

activesubstancenameOMEGA-3-ACID ETHYL ESTERS

openFDA Info on Medication

Application NumberANDA204940Brand NameLOVAZAGeneric NameOMEGA-3-ACID ETHYL ESTERSManufacturersWoodward Pharma Services LLCproduct_ndc69784-420Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsOMEGA-3-ACID ETHYL ESTERSRXCUI577208, 607044spl_idecc17d6c-6691-444d-b2e7-f0adde51d804spl_set_idc1920576-1b04-4b20-bb00-061f09032574Package NDC69784-420-12, 69784-420-36, 69784-420-60UNIID87YGH4Z0Q

11)

drugcharacterization2medicinalproductADDERALLdrugstructuredosagenumb15drugstructuredosageunit003drugdosagetext15 MG, UNKdrugdosageformCAPSULEdrugindicationSOMNOLENCEdrugstartdateformat102drugstartdate01/01/2007drugenddateformat102drugenddate11/11/2015drugrecurreadministration3

activesubstance

activesubstancename AMPHETAMINE ASPARTATE\AMPHETAMINE SULFATE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMP ...

openFDA Info on Medication

12)

drugcharacterization2medicinalproductAMBIENdrugdosagetextUNKdrugdosageformTABLETdrugindicationPRODUCT USED FOR UNKNOWN INDICATIONdrugstartdateformat102drugstartdate11/11/2015drugenddateformat102drugenddate11/11/2015drugrecurreadministration3

activesubstance

activesubstancenameZOLPIDEM TARTRATE

openFDA Info on Medication

Application NumberNDA021774, NDA019908Brand NameAMBIEN CR, AMBIENGeneric NameZOLPIDEM TARTRATEManufacturerssanofi-aventis U.S. LLCproduct_ndc0024-5501, 0024-5521, 0024-5401, 0024-5421Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsZOLPIDEM TARTRATERXCUI854880, 854882, 854894, 854896, 854873, 854875, 854876, 854878spl_id8138a0a9-168c-46d2-b13e-e7e84f27eaee, c8f05d12-bc35-43cb-8b65-588bec02c73dspl_set_id404c858c-89ac-4c9d-8a96-8702a28e6e76, c36cadf4-65a4-4466-b409-c82020b42452Package NDC 0024-5501-31, 0024-5501-10, 0024-5521-31, 0024-5521-50, 0024-5521-10, 0024-5401- ... UNIIWY6W63843K

summary

narrativeincludeclinicalCASE EVENT DATE: 2015

Adverse Event Report

Report

Report Duplicate

Primary Source

Sender

Receiver

Patient

Reaction

1)

2)

3)

4)

5)

Drug

1)

activesubstance

openFDA Info on Medication

2)

activesubstance

openFDA Info on Medication

3)

activesubstance

openFDA Info on Medication

4)

activesubstance

5)

activesubstance

openFDA Info on Medication

6)

activesubstance

openFDA Info on Medication

7)

activesubstance

openFDA Info on Medication

8)

activesubstance

openFDA Info on Medication

9)

activesubstance

10)

activesubstance

openFDA Info on Medication

11)

activesubstance

openFDA Info on Medication

12)

activesubstance

openFDA Info on Medication

summary

Media

Newsletter

Follow us

Connect with us